NPPA Fixes Retail Price Of 51 Formulations, Details
New Delhi: Through a recent notification, the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of the 51 formulations including those used to treat type 2 diabetes, bacterial infections, and others.
This came in line with the decision of the 114th Authority meeting dated 19.06.2023, where the authority discussed the new drug applications for price fixation under para 5 and 15 of DPCO 2013.
These include Skymap Healthcare & Healing Pharma's Ciprofloxacin & Dexamethasone Eye Drops, Cris Pharma& Mankind Prime Lab's Paracetamol, Phenylephrine and Chlorpheniramine Drops, Akums Drugs & Eris Life science's Paroxetine Controlled release & Clonazepam Capsules.
The list further includes Etoricoxib and Paracetamol Tablets manufactured and marketed by Pfizer, Linagliptin, and Metformin Hydrochloride Tablets manufactured and marketed by Intas Pharmaceuticals, Dapagliflozin, Sitagliptin and Metformin Hydrochloride Tablets manufactured and marketed by Sun Pharma Laboratories, Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet marketed by Alkem Laboratories and etc.
This comes in the exercise of the powers conferred by paragraphs 5, 11, and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S. O. 5249(E) dated 11th November 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority has fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit, and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3),(4) and (5) thereof;
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1 | Ciprofloxacin & Dexamethasone Eye Drops | Composition: Ciprofloxacin Hydrochloride IP eq. to Ciprofloxacin 0.3% w/v Dexamethasone IP 0.1% w/v Benzalkonium Chlorid Sodium IP 0.02% v/v (As preservative) Sterile aqueous Vehicle q.s. | 1 ml | M/s Skymap Healthcare Pvt. Ltd. /M/s Healing Pharma India Pvt. Ltd. | 2.05 |
2 | Paracetamol, Phenylephrine and Chlorphenirami ne Drops | Each ml (approximately 30 drops) contains: Paracetamol IP 125mg Phenylephrine Hydrochloride IP 2.5mg Chlorpheniramine Maleate IP 1.0mg | 1 ml | M/s Cris Pharma (I) Ltd.. / M/s Mankind Prime Labs Pvt. Ltd. | 4.15 |
3 | Paroxetine Controlled release & Clonazepam Capsules | Each hard gelatine capsule contains: Paroxetine Hydrochloride IP eq. to Paroxetine 25mg (As enteric coated controlled release tablet) &Clonazepam IP 0.5mg (as immediate release tablet) | 1 Capsule | M/s Akums Drugs & Pharmaceuticals Limited / M/s Eris Lifesciences Limited | 15.81 |
4 | Etoricoxib and Paracetamol Tablets | Each Film Coated tablet contains: Etoricoxib IP 60 mg Paracetamol IP 325 mg | 1 Tablet | M/s Pfizer Limited | 8.99 |
5 | Linagliptin and Metformin | Each film coated tablet contains: | 1 Tablet | M/s Intas Pharmaceuticals | 8.97 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Hydrochloride Tablets | Linagliptin IP 2.5mg Metformin Hydrochloride IP 500mg | Ltd. | |||
6 | Linagliptin and Metformin Hydrochloride Tablets | Each film coated tablet contains: Linagliptin IP 2.5mg Metformin Hydrochloride IP 1000mg | 1 Tablet | M/s Intas Pharmaceuticals Ltd. | 9.60 |
7 | Linagliptin and Metformin Hydrochloride Tablets | Each film coated tablet contains: Linagliptin IP 2.5mg Metformin Hydrochloride IP 500mg | 1 Tablet | M/s Torrent Pharmaceuticals Ltd. | 8.90 |
8 | Linagliptin and Metformin Hydrochloride Tablets | Each film coated tablet contains: Linagliptin IP 2.5mg Metformin Hydrochloride IP 1000mg | 1 Tablet | M/s Torrent Pharmaceuticals Ltd. | 9.50 |
9 | Linagliptin and Metformin Hydrochloride Tablets | Each film coated tablet contains: Linagliptin IP 2.5mg Metformin Hydrochloride IP 500mg | 1 Tablet | M/s Unison Pharmaceuticals Pvt. Ltd. | 8.97 |
10 | Linagliptin and Metformin Hydrochloride Tablets | Each film coated tablet contains: Linagliptin IP 2.5mg Metformin Hydrochloride IP 1000mg | 1 Tablet | M/s Unison Pharmaceuticals Pvt. Ltd. | 9.60 |
11 | Dapagliflozin, Sitagliptin and Metformin Hydrochloride (as Extended Release) Tablets | Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100mg Metformin Hydrochloride IP 500mg (as Extended Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Wockhardt Limited | 16.95 |
12 | Dapagliflozin, Sitagliptin and Metformin Hydrochloride (as Extended Release) Tablets | Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100mg Metformin Hydrochloride IP 1000mg (as Extended Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Wockhardt Limited | 17.84 |
13 | Dapagliflozin, Sitagliptin and Metformin | Each film coated bilayered tablet contains: Dapagliflozin Propanediol | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Aristo | 19.57 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Hydrochloride (ER) Tablets | Monohydrate eq. to Dapagliflozin 10mg Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100mg Metformin Hydrochloride IP 500mg (As an Extended- release form) | Pharmaceuticals Pvt. Ltd. | |||
14 | Dapagliflozin, Sitagliptin and Metformin Hydrochloride (ER) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100mg Metformin Hydrochloride IP 1000mg (As an Extended release form) | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Aristo Pharmaceuticals Pvt. Ltd. | 20.67 |
15 | Dapagliflozin, Sitagliptin and Metformin Hydrochloride Tablets | Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5mg Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 50mg Metformin Hydrochloride IP 500mg | 1 Tablet | M/s Sun Pharma Laboratories Limited | 13.63 |
16 | Dapagliflozin, Sitagliptin and Metformin Hydrochloride Tablets | Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5mg Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg | 1 Tablet | M/s Sun Pharma Laboratories Limited | 14.60 |
17 | Dapagliflozin, Vildagliptin (SR) and Metformin Hydrochloride (SR) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 500mg (as Sustained Release) | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Alkem Laboratories Ltd. | 18.76 |
18 | Dapagliflozin, Vildagliptin (SR) and Metformin | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Alkem Laboratories Ltd. | 19.87 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Hydrochloride (SR) Tablets | Dapagliflozin 10mg Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 1000mg (as Sustained Release) | ||||
19 | Dapagliflozin, Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each uncoated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5mg Vildagliptin IP (As Sustained release) 100mg Metformin Hydrochloride IP 500mg (as Sustained Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Eris Lifesciences Limited | 16.18 |
20 | Dapagliflozin, Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each uncoated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5mg Vildagliptin IP (As Sustained release) 100mg Metformin Hydrochloride IP 1000mg (as Sustained Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Eris Lifesciences Limited | 17.04 |
21 | Dapagliflozin, Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each uncoated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5mg Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride (as Sustained Release) IP 500mg | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Emcure Pharmaceuticals Limited | 16.18 |
22 | Dapagliflozin, Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each uncoated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5mg Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride (as Sustained Release) IP 1000mg | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Emcure Pharmaceuticals Limited | 17.04 |
23 | Dapagliflozin, Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each uncoated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride (as | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Mankind Pharma Ltd. | 20.11 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Sustained Release) IP 1000mg | |||||
24 | Dapagliflozin, Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each uncoated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride (as Sustained Release) IP 500mg | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Mankind Pharma Ltd. | 19.00 |
25 | Dapagliflozin, Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each uncoated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5mg Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride (as Sustained Release) IP 500mg | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Intas Pharmaceuticals Ltd. | 12.50 |
26 | Dapagliflozin, Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each uncoated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5mg Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride (as Sustained Release) IP 1000mg | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Intas Pharmaceuticals Ltd. | 15.00 |
27 | Dapagliflozin, Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each uncoated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5mg Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride (as Sustained Release) IP 500mg | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Zydus Healthcare Limited | 16.04 |
28 | Dapagliflozin, Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each uncoated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5mg Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride (as Sustained Release) IP 1000mg | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Zydus Healthcare Limited | 16.98 |
29 | Dapagliflozin, | Each uncoated bilayered | 1 Tablet | M/s Exemed | 19.11 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride (as Sustained Release) IP 500mg | Pharmaceuticals / M/s Alembic Pharmaceuticals Limited | |||
30 | Dapagliflozin, Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride (as Sustained Release) IP 500mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Unison Pharmaceuticals Pvt. Ltd. | 14.90 |
31 | Dapagliflozin, Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride (as Sustained Release) IP 1000mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Unison Pharmaceuticals Pvt. Ltd. | 16.44 |
32 | Dapagliflozin, Vildagliptin (SR) and Metformin Hydrochloride (SR) Tablets | Each uncoated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 500mg (as Sustained Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Torrent Pharmaceuticals Limited | 19.00 |
33 | Dapagliflozin, Vildagliptin (SR) and Metformin Hydrochloride (SR) Tablets | Each uncoated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 1000mg (as Sustained Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Torrent Pharmaceuticals Limited | 20.11 |
34 | Dapagliflozin, Vildagliptin (As Sustained release) and Metformin | Each uncoated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Alembic Pharmaceuticals Limited | 19.11 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Hydrochloride (as Sustained Release) Tablets | Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride (as Sustained Release) IP 500mg | ||||
35 | Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet | Each uncoated bilayered tablet contains: Sitagliptin Phosphate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 500mg (Sustained Release Form) | 1 Tablet | M/s Alkem Health Science (A Unit of Alkem Laboratories Ltd.) / M/s Alkem Laboratories Ltd | 16.33 |
36 | Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet | Each uncoated bilayered tablet contains: Sitagliptin Phosphate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 1000mg (Sustained Release Form) | 1 Tablet | M/s Alkem Health Science (A Unit of Alkem Laboratories Ltd.) / M/s Alkem Laboratories Ltd | 17.69 |
37 | Vildagliptin (SR) & Metformin Hydrochloride (SR) Tablets | Each film coated bilayered tablet contains: Vildagliptin IP (As Sustained Release) 100mg Metformin Hydrochloride IP (As Sustained Release) 500mg | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Intas Pharmaceuticals Ltd. | 12.11 |
38 | Vildagliptin (SR) & Metformin Hydrochloride (SR) Tablets | Each film coated bilayered tablet contains: Vildagliptin IP (As Sustained Release) 100mg Metformin Hydrochloride IP (As Sustained Release) 500mg | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Torrent Pharmaceuticals Ltd. | 12.11 |
39 | Vildagliptin (SR) and Metformin Hydrochloride (SR) Tablets | Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 500mg (as Sustained Release) | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Zydus Healthcare Limited | 12.28 |
40 | Vildagliptin (SR) and Metformin Hydrochloride (SR) Tablets | Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 500mg (as Sustained Release) | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Lupin Limited | 12.28 |
41 | Vildagliptin (SR) and Metformin | Each film coated bilayered tablet contains: | 1 Tablet | M/s Synokem Pharmaceuticals | 12.28 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Hydrochloride (SR) Tablets | Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 500mg (as Sustained Release) | Ltd. / M/s Eris Lifesciences Limited | |||
42 | Vildagliptin (SR) and Metformin Hydrochloride (SR) Tablets | Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 500mg (as Sustained Release) | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Cipla Limited | 12.28 |
43 | Vildagliptin (SR) & Metformin Hydrochloride (SR) Tablets | Each film coated bilayered tablet contains: Vildagliptin IP (As Sustained Release) 100mg Metformin Hydrochloride IP (As Sustained Release) 1000mg | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Intas Pharmaceuticals Ltd. | 13.65 |
44 | Vildagliptin (SR) & Metformin Hydrochloride (SR) Tablets | Each film coated bilayered tablet contains: Vildagliptin IP (As Sustained Release) 100mg Metformin Hydrochloride IP (As Sustained Release) 1000mg | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Torrent Pharmaceuticals Ltd. | 13.65 |
45 | Vildagliptin (SR) and Metformin Hydrochloride (SR) Tablets | Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 1000mg (as Sustained Release) | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Lupin Limited | 13.82 |
46 | Vildagliptin (SR) and Metformin Hydrochloride (SR) Tablets | Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 1000mg (as Sustained Release) | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Zydus Healthcare Limited | 13.82 |
47 | Vildagliptin (SR) and Metformin Hydrochloride (SR) Tablets | Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 1000mg (as Sustained Release) | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Eris Lifesciences Limited | 13.82 |
48 | Vildagliptin (SR) and Metformin Hydrochloride (SR) Tablets | Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Cipla Limited | 13.82 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1000mg (as Sustained Release) | |||||
49 | Vildagliptin (SR) and Metformin Hydrochloride (SR) Tablets | Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 500mg (as Sustained Release) | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Mankind Pharma Ltd. | 12.14 |
50 | Vildagliptin (SR) and Metformin Hydrochloride (SR) Tablets | Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 1000mg (as Sustained Release) | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Mankind Pharma Ltd. | 13.68 |
51 | Zinc Sulfate Monohydrate, Sodium Citrate, Potassium Chloride, Sodium Chloride, Dextrose Anhydrous Sachet | Each 4.4g sachet contains: Zinc Sulfate Monohydrate IP 0.011g Sodium Citrate IP 0.58g Potassium Chloride IP 0.30g Sodium Chloride IP 0.52g Dextrose Anhydrous IP 2.70g | Per Sachet of 4.4 gm | M/s Acme Diet Care Pvt. Ltd. / M/s RPG Life Sciences Ltd. | 6.12 |
The notification further added,
(a) The manufacturer of the above-mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above-said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from the date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above-mentioned retail price is applicable only to the individual manufacturer/marketer as mentioned above i.e. who has applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of the retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Columns (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.